1,2,3,4-四氢-2-(碘甲基)-萘 | 104325-74-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 1,2,3,4-四氢-2-(碘甲基)-萘
• 英文名称: 2-(iodomethyl)-1,2,3,4-tetrahydronaphthalene
• CAS: 104325-74-8
• 化学式: C₁₁H₁₃I
• 分子量: 272.129
• InChiKey: GRNVNSSNONVUCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1,2,3,4-四氢-2-(碘甲基)-萘 、 1-(3-hydroxyphenyl)-1-hexanol 在 sodium hydroxide 作用下， 以 四氢呋喃 、 正己烷 、 二甲基亚砜 、 乙酸乙酯 为溶剂， 生成 2-(3-(1-hydroxyhexyl)phenoxymethyl)-1,2,3,4-tetrahydro naphthalene
  参考文献：
  名称：

  Certain [3-(1-hydroxy hexyl-tetrahydro)naphthalenes], the corresponding

  摘要：

  该发明涉及几种芳氧基-烷基醇，例如1-(3-(1-羟基-1-甲基己基)苯氧甲基)-2-甲氧基萘，2-(1-(3-(1-羟基-2,2-二甲基己基)苯氧)乙基萘，1-(3-6-苯氧基-1-羟基己基)苯氧甲基)-4-甲氧基萘，2-(3-(1-羟基己基)苯氧甲基)萘和2-(3-(1-羟基己基)苯氧甲基)-1,2,3,4-四氢萘，以及它们的制备方法和用于治疗哺乳动物的炎症和过敏症状的用途。

  公开号：

  US04778931A1
• 作为产物：
  描述：

  咪唑 、 1,4-苯并二恶烷-6-甲醛 在 碘 、 三苯基膦 作用下， 以 正己烷 、 苯 为溶剂， 以90%的产率得到1,2,3,4-四氢-2-(碘甲基)-萘
  参考文献：
  名称：

  Imidiazoles having reduced side effects

  摘要：

  用于治疗疼痛、特别是慢性疼痛、青光眼或高眼压的方法和化合物，具有降低心血管或镇静副作用。还包括制备和使用这些化合物的方法。

  公开号：

  US06841684B2

文献信息

• Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors
  申请人：Allergan Sales, Inc.

  公开号：US20020156076A1

  公开（公告）日：2002-10-24

  Compounds having adrenergic activity which are a selective agonists for one or both of the &agr; 2B and &agr; 2c adrenoceptor receptor subtypes in preference to the &agr; 2A adrenoceptor receptor subtype; the active compound being selected from the group consisting of compounds having the formula 1 wherein the dotted lines represent optional bonds provided that two double bonds may not share a common carbon atom; R is H or lower alkyl; X is S or C(H)R 1 , wherein R 1 is H or lower alkyl, but R 1 is absent when the bond between X and the ring represented by 2 is a double bond; Y is O, N, S, (CR 1 2 ) y , wherein y is an integer of from 1 to 3, —CH═CH— or —Y 1 CH 2 —, wherein Y 1 is O, N or S; x is an integer of 1 or 2, wherein x is 1 when R 2 , R 3 or R 4 is bound to an unsaturated carbon atom and x is 2 when R 2 , R 3 or R 4 is bonded to a saturated carbon atom; R 2 is H, lower alkyl, halogen, hydroxy, lower alkoxy, lower alkenyl, acyl or lower alkynyl, or, when attached to a saturated carbon atom, R 2 may be oxo; R 3 and R 4 are, each, H, lower alkyl, halogen, lower alkenyl, acyl, lower alkynyl, aryl, heteroaryl, or sub stituted aryl or heteroaryl, wherein said substituent is halogen, lower alkyl, lower alkoxy, lower alkenyl, acyl, lower alkynyl, nitro, cyano, trifluoromethyl, hydroxy, or phenyl or, together, are —(C(R 2 )x)z—; —Y 1 (C(R 2 )x)z′—; —Y 1 (C(R 2 )x)y Y 1 —; —(C(R 2 )x)—Y 1 —(C(R 2 )x)—; —(C(R 2 )x)—Y 1 —(C(R 2 )x)—(C(R 2 )x)— and —Y 1 —(C(R 2 )x)—Y 1 —(C(R 2 )x)— wherein z is an integer of from 3 to 5, z′ is an integer of from 2 to 4 and x and y are as defined above, and further either end of each of these divalent moieties may attach at either R3 or R4 to form a condensed ring structure and the rings formed may be totally unsaturated, partially unsaturated, or totally saturated; and being useful for treating muscle spasticity including hyperactive micturition, diarrhea, diuresis, withdrawal syndromes, pain including neuropathic pain, neurodegenerative diseases, memory and cognition deficits, psychoses including manic disorders and anxiety, hypertension, cardiac ischemia, congestive heart failure, and nasal congestion without sedating or cardiovascular side effects.

  具有肾上腺素活性的化合物，是选择性激动剂，优先作用于α2B和α2C肾上腺素受体亚型中的一个或两个，而不是α2A肾上腺素受体亚型；所述活性化合物从以下化合物组中选择，其具有下列式1的化合物，其中虚线代表可选键，但两个双键不能共用一个碳原子；R为H或较低的烷基；X为S或C(H)R1，其中R1为H或较低的烷基，但当X与由2表示的环之间的键为双键时，R1不存在；Y为O、N、S、(CR12)y，其中y为1至3的整数，—CH2CH—或—Y1CH2—，其中Y1为O、N或S；x为1或2的整数，当R2、R3或R4与不饱和碳原子结合时，x为1，当R2、R3或R4与饱和碳原子结合时，x为2；R2为H、较低的烷基、卤素、羟基、较低的烷氧基、较低的烯基、酰基或较低的炔基，或者当连接到饱和碳原子时，R2可能为酮基；R3和R4分别为H、较低的烷基、卤素、较低的烯基、酰基、较低的炔基、芳基、杂环芳基或取代的芳基或杂环芳基，其中所述取代基为卤素、较低的烷基、较低的烷氧基、较低的烯基、酰基、较低的炔基、硝基、氰基、三氟甲基、羟基或苯基，或者共同为—(C(R2)x)z—；—Y1(C(R2)x)z′—；—Y1(C(R2)x)y Y1—；—(C(R2)x)—Y1—(C(R2)x)—；—(C(R2)x)—Y1—(C(R2)x)—(C(R2)x)—和—Y1—(C(R2)x)—Y1—(C(R2)x)—其中z为3至5的整数，z′为2至4的整数，x和y如上所定义，而且这些二价基团的每一端都可以连接到R3或R4中的任一端，形成一个紧凑的环结构，所形成的环可以是完全不饱和的、部分不饱和的或完全饱和的；并且适用于治疗肌肉痉挛，包括过度活跃的小便、腹泻、利尿、戒断综合征、包括神经病理性疼痛、神经退行性疾病、记忆和认知缺陷、精神病，包括躁狂障碍和焦虑、高血压、心肌缺血、充血性心力衰竭和鼻塞，无镇静或心血管副作用。
• Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
  申请人：ALLERGAN SALES, INC.

  公开号：US20030023098A1

  公开（公告）日：2003-01-30

  Methods and compounds for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects. Also included are methods of making and using such compounds.

  用于治疗疼痛、特别是慢性疼痛、青光眼或高眼压的方法和化合物，具有减少心血管或镇静副作用。还包括制备和使用这些化合物的方法。
• Anti-inflammatory/anti-allergic compounds
  申请人：RHONE-POULENC RORER PHARMACEUTICALS INC.

  公开号：EP0181568A2

  公开（公告）日：1986-05-21

  Compounds of the formula: and salts thereof, wherein Ar1 is a nitrogen, sulfur, oxygen heterocyclic ring or aromatic ring; Ar is a phenyl ring or a nitrogen, oxygen or sulfur heterocyclic ring; Ar and Ar1 may be fully substituted or less than fully substituted with H, CH3, lower alkyl, aryl, aralkyl, halo, hydroxy, lower alkoxy, CF3, carboxy, alkylcarboxy, arylcarboxy, alkylcarbalkoxy, alkanoyl, formyl, oxo, nitrilo, amino, aminoalkyl, alkylamine, carboxamide, aryloxy, nitro, sulfonyl, sulfonamide, thio, or alkylthio; X = -O(CHR1)n-, , -NR2(CHR1)n-alkylene of up to 2 carbon atoms in the principal chain and up to a total of 4 carbon atoms, Z is an alkylene chain containing up to 10 carbon atoms in the principal chain and a total of up to 12 carbon atoms and from 0 to 2 double bonds and the said alkylene chain may be attached to Ar through an oxygen, sulfur or amino nitrogen atom, and when n'=2, one of the R substituents may be halogen on an omega carbon of the alkylene chain Z; when n'=1, R is a substituent attached to one of the carbon atoms of Z selected from the group consisting of =0, OR3, SR3, N(R2)2 and R,, -COR4 and when n'=2 one R is previously defined and the additional R is a substituent attached to one of the carbon atoms of Z selected from the group consisting of =O, OR3, SRa, N(R2)2, -COR4, lactone and halo; R1 is H or CH3; R2 is H, lower alkyl, aryl or aralkyl; R3 is H, lower alkyl, lower alkanoyl, aryl, aralkyl or substituted aryl in which the substituent is halo, lower alkyl or lower alkoxy; R4 is OR2 or N(R2)2; n = 0 or 1; n' = 1 to 7; and n" = 0, 1 or 2. 2. A compound of the formula: and salts thereof, wherein Ar1 is quinolyl; Ar is a phenyl, pyridyl or quinolyl ring; X = -O(CHR1)n-, -, NR2(CHR1)n-, alkylene of up to 2 carbon atoms in the principal chain and up to a total of 4 carbon atoms,

  式化合物及其盐类 及其盐类，其中 Ar1 是氮、硫、氧杂环或芳香环； Ar 是苯环或氮、氧或硫杂环； Ar 和 Ar1 可被 H、CH3、低级烷基、芳基、芳烷基、卤代、羟基、低级烷氧基、CF3、羧基、烷基羧基、芳基羧基、烷基羧基、烷基烷氧基、烷酰基、甲酰基、氧代、氮代、氨基、氨基烷基、烷基胺、羧酰胺、芳氧基、硝基、磺酰基、磺酰胺、硫代或烷硫基完全取代或未完全取代； X = -O(CHR1)n-、 、-NR2(CHR1)n-主链上最多 2 个碳原子且总共最多 4 个碳原子的烯烃、 当 n'=2 时，R 取代基之一可以是位于亚烷基链 Z 的欧米伽碳上的卤素； 当 n'=1 时，R 是连接到 Z 的一个碳原子上的取代基，该取代基选自由 =0、OR3、SR3、N(R2)2 和 R、-COR4 组成的组，当 n'=2 时，一个 R 如前定义，另外一个 R 是连接到 Z 的一个碳原子上的取代基，该取代基选自由 =O、OR3、SRa、N(R2)2、-COR4、内酯和卤素组成的组； R1 是 H 或 ； R2 是 H、低级烷基、芳基或芳烷基； R3 是 H、低级烷基、低级烷酰基、芳基、芳烷基或取代芳基，其中取代基是卤素、低级烷基或低级烷氧基； R4 是 OR2 或 N（R2）2； n = 0 或 1 n' = 1 至 7；以及 n" = 0、1 或 2。 2.式中的化合物 及其盐类、 其中 Ar1 是喹啉基； Ar 是苯基、吡啶基或醌基环； X = -O(CHR1)n-、 -、NR2(CHR1)n-、主链上最多 2 个碳原子且总共最多 4 个碳原子的亚烷基、
• Dihydro and tetrahydroquinoline derivatives
  申请人：USV PHARMACEUTICAL CORPORATION

  公开号：EP0190722A2

  公开（公告）日：1986-08-13

  This invention relates to novel lipoxygenase inhibitors possessing anti-inflammatory and anti-allergic activities. The present new compounds are di-and tetra-hydroquinoline or di- and tetra-hydronapthalene derivatives, more particularly, 1,2-, 1,4-, 5,6-, or 7,8-dihydro; 1,2,3,4,-tetrahydro-; 5,8-dihydro-; or 5,6,7,8-tetrahydroquinoline or napthalene derivatives of a compound of the formula: and oxides, quaternary ammonium salts and acid salts thereof; wherein A is CH or N; Z is an alkylene chain containing up to 10 carbon atoms in the principal chain and a total of up to 12 carbon atoms and the said alkylene chain may be attached to the phenyl group through an oxygen atom; R is the substituent OR6 attached to one of the carbon atoms of Z in which R6 is H, lower alkyl or phenyl; X is -0(CHR5)m-, alkylene of up to 2 carbon atoms in the principal chain and up to a total of 4 carbon atoms or - -C (CHR5)m-, wherein R5 is H or CH3; OH R1, R2, R3, and R4, are each H or OH; n' = 1 or 2; and m = 1 or 2.

  本发明涉及具有抗炎和抗过敏活性的新型脂氧合酶抑制剂。本发明的新化合物是二氢和四氢喹啉或二氢和四氢萘衍生物，特别是 1,2-、1,4-、5,6- 或 7,8-二氢；1,2,3,4,-四氢；5,8-二氢；或 5,6,7,8-四氢喹啉或萘衍生物的式化合物： 及其氧化物、季铵盐和酸盐； 其中 A 是 CH 或 N Z 是亚烷基链，在主链中最多含有 10 个碳原子，总共最多含有 12 个碳原子，所述亚烷基链可通过一个氧原子连接到苯基上； R 是连接到 Z 的一个碳原子上的取代基 OR6，其中 R6 是 H、低级烷基或苯基； X 是-0(CHR5)m-、主链上最多 2 个碳原子且总共最多 4 个碳原子的亚烷基或-C (CHR5)m- -C（CHR5）m-，其中 R5 是 H 或 CH3； OH R1、R2、R3 和 R4 各为 H 或 OH； n' = 1 或 2；以及 m = 1 或 2。
• Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors
  申请人：Allergan, Inc.

  公开号：EP1413576A2

  公开（公告）日：2004-04-28

  Coumpounds having adrenergic activity which are selective agonists for one or both of the α2B and α2C adrenoceptor receptor subtypes in preference to the α2A adrenoceptor receptor subtype; the active compound being selected from the group consisting of compounds having formula (I) wherein the dotted lines represent optional bonds provided that two double bonds may not share a common carbon atom; R is H or lower alkyl; X is S or C(H)R1, wherein R1 is H or lower alkyl, but R1 is absent when the bond between X and the ring represented by formula (a) is a double bond; Y is O, N, S, (CR12)y, wherein y is an integer of from 1 to 3, -CH=CH- or -Y1CH2-, wherein Y1 is O, N or S; x is an integer of 1 or 2, wherein x is 1 when R2, R3 or R4 is bound to a saturated carbon atom and x is 2 when R2, R3 or R4 is bound to a saturated carbon atom; R2 is H, lower alkyl, halogen, hydroxy or lower alkoxy, or, when attached to a saturated carbon atom, R2 may be oxo; R3 and R4 are, each, H, lower alkyl, hydroxy, lower alkoxy, or phenyl or, together, are -(C(R2)x)z-; -Y1(C(R2)x)z'-; -Y1(C(R2)x)yY1-; -(C(R2)x)-Y1-(C(R2)x)-; -(C(R2)x)-Y1-(C(R2)x)-(C(R2)x)- and -Y1-(C(R2)x)-Y1-(C(R2)x)- wherein z is an integer of from 3 to 5, z' is an integer of from 2 to 4 and x and y are as defined above, and further either end of each of these divalent moieties may attach at either R3 or R4 to form a condensed ring structure and the rings formed may be totally unsaturated, partially unsaturated, or totally saturated; and being useful for treating muscle spasticity including hyperactive micturition, diarrhea, diuresis, withdrawal syndromes, pain including neuropathic pain, neurodegenerative diseases, memory and cognition deficits, psychoses including manic disorders and anxiety, hypertension, cardiac ischemia, congestive heart failure, and nasal congestion without sedating or cardiovascular side effects.

  具有肾上腺素能活性的偶联化合物，是一种或两种 α2B和α2C肾上腺素受体亚型的选择性激动剂，优于α2A肾上腺素受体亚型；活性化合物选自由式(I)组成的化合物组，其中虚线代表任选键，但两个双键不得共用一个碳原子；R是H或低级烷基；X 是 S 或 C(H)R1，其中 R1 是 H 或低级烷基，但当 X 与式 (a) 所代表的环之间的键是双键时，R1 不存在； Y 是 O、N、S、(CR12)y（其中 y 是 1 至 3 的整数）、-CH=CH- 或 -Y1CH2-，其中 Y1 是 O、N 或 S；x 是 1 或 2 的整数，其中，当 R2、R3 或 R4 与饱和碳原子结合时，x 为 1，当 R2、R3 或 R4 与饱和碳原子结合时，x 为 2；R2 是 H、低级烷基、卤素、羟基或低级烷氧基，或者，当与饱和碳原子连接时，R2 可以是氧代；R3 和 R4 分别是 H、低级烷基、羟基、低级烷氧基或苯基，或者合在一起是-(C(R2)x)z-；-Y1(C(R2)x)z'-；-Y1(C(R2)x)yY1-；-(C(R2)x)-Y1-(C(R2)x)-；-(C(R2)x)-Y1-(C(R2)x)-(C(R2)x)-和-Y1-(C(R2)x)-Y1-(C(R2)x)- 其中 z 是 3 至 5 的整数，z'是 2 至 4 的整数，x 和 y 如上文所定义、此外，这些二价分子的任何一端都可以连接到 R3 或 R4 上，形成缩合环结构，所形成的环可以是完全不饱和、部分不饱和或完全饱和的；可用于治疗肌肉痉挛（包括排尿亢进）、腹泻、利尿、戒断综合征、疼痛（包括神经性疼痛）、神经退行性疾病、记忆和认知障碍、精神病（包括躁狂症和焦虑症）、高血压、心脏缺血、充血性心力衰竭和鼻塞，且无镇静或心血管副作用。